1. 多巴酚丁胺联合胺碘酮在 ICU 心律失常患者中应用及对相关蛋白影响.
- Author
-
武 蕊, 黄牧坤, 朱玉婷, 杨 荣, and 骆梦华
- Subjects
- *
ARRHYTHMIA , *C-reactive protein , *BRAIN natriuretic factor , *DRUG side effects , *HEART beat , *TREATMENT effectiveness - Abstract
Objective: To explore the effect of dobutamine combined with amiodarone in the clinical treatment of arrhythmia patients in ICU. Methods: 72 patients with arrhythmias in ICU treated in our hospital from April 2019 to may 2022 were divided into matched group and experimental group by average method, with 36 cases in each group. The matched group was treated with dobutamine, while the experimental group was treated with dobutamine + amiodarone. The cardiac function indexes, BNP and HS CRP levels, the frequency of arrhythmias, average heart rate, clinical efficacy, adverse cardiovascular events and drug safety were compared between the two groups. Results: There was no difference in the levels of LVEF, LVEDd and LVESD between the two groups before treatment (P>0.05). After treatment, the levels of LVEF increased and the levels of LVEDd and LVESD decreased in the two groups. After treatment, the changes of the above indexes in the experimental group were greater than those in the matched group (P<0.05); Before treatment, there was no difference in the levels of BNP and hs CRP between the two groups (P>0.05). After treatment, the levels of BNP and hs CRP in the two groups decreased, and after treatment, the levels of BNP and hs CRP in the experimental group were lower than those in the matched group (P<0.05); Before treatment, there was no difference in the number of arrhythmias and average heart rate between the two groups (P>0.05). After treatment, the number of arrhythmias and average heart rate in the two groups decreased, and after treatment, the number of arrhythmias in the experimental group was less than that in the matched group, and the average heart rate was lower than that in the matched group (P<0.05); The effective rate of clinical treatment in the experimental group was 94.44 %, and that in the matched group was 69.44 %. The effective rate of clinical treatment in the experimental group was higher than that in the matched group (P<0.05); The incidence of adverse cardiovascular events and adverse reactions in the experimental group were lower than those in the matched group (P<0.05). Conclusion: Dobutamine combined with amiodarone has a significant therapeutic effect on improving cardiac function in ICU arrhythmia patients, reducing the number of arrhythmias, stabilizing heart rate, and reducing the level of brain natriuretic peptide and high-sensitivity C-reactive protein, and the patient develops after treatment. There are few adverse cardiovascular events and adverse drug reactions, and it has a satisfactory drug safety. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF